By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – BG Medicine today lowered the expected share price for its proposed initial public offering to $7, the second time it has lowered its price since filing for the IPO a year ago.
Registering provides access to this and other free content.
Already have an account?Login Now.
The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.
The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.
The first Reproducibility Project: Cancer Biology papers show mixed results.
In Nature this week: mobile phone-based targeted DNA sequencing, and more.